160
Participants
Start Date
November 9, 2021
Primary Completion Date
November 10, 2022
Study Completion Date
December 7, 2023
KX-826 dosed at 2.5mg
2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
KX-826 dosed at 2.5mg
2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
KX-826 dosed at 5 mg
5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
KX-826 dosed at 5 mg
5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
Matching placebo to KX-826
Placebo applied topically to scalp once daily for 24 weeks
Matching placebo to KX-826
Placebo applied topically to scalp twice daily for 24 weeks
Beijing Friendship Hospital, Capital Medical University, Beijing
Beijing Tongren Hospital, Capital Medical University, Beijing
China-Japan Friendship Hospital, Beijing
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Xiangya Hospital Central South University, Changsha
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Dermatology Hospital of Southern Medical University, Guangzhou
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Huashan Hospital, Fudan University, Shanghai
Shenzhen People's Hospital, Shenzhen
The First Hospital of Hebei Medical University, Shijiazhuang
Suining Central Hospital, Suining
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Suzhou Koshine Biomedica, Inc.
INDUSTRY